Format

Send to

Choose Destination
Atherosclerosis. 2010 Jul;211(1):333-6. doi: 10.1016/j.atherosclerosis.2010.02.024. Epub 2010 Feb 24.

Metalloproteinase 2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction.

Author information

1
Department of Morphology and Embryology, University of Ferrara, and Cardiovascular Institute, Azienda Ospedaliera-uNiversitaria S. Anna, Via Fossato di Mortara 66, 44100 Ferrara, Italy. paola.secchiero@unife.it

Abstract

BACKGROUND:

This study was designed to evaluate the potential role of metalloproteinase 2 (MMP2) in promoting the cleavage of TNF-related apoptosis inducing ligand (TRAIL), whose circulating levels are decreased after acute myocardial infarction (AMI).

METHODS:

The levels of MMP2 and of tissue inhibitor of metalloprotease 2 (TIMP2), as well as of TRAIL, were measured by ELISA in the serum of AMI patients and in the culture supernatant of endothelial cells.

RESULTS:

In AMI patients the serum levels of TRAIL showed a significant inverse correlation with the MMP2/TIMP2 ratio. In vitro MMP2 induced the cleavage of recombinant TRAIL and inactivated its ability of inducing apoptosis. Moreover, exposure of endothelial cells to TNF-alpha increased the MMP2/TIMP2 ratio in the culture supernatant.

CONCLUSIONS:

An impaired MMP2/TIMP2 ratio might be involved in the decreased levels of circulating TRAIL observed after AMI.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center